Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition. (PubMed, bioRxiv) - Sep 25, 2026 - "Daraxonrasib in combination with the MEK inhibitor trametinib prevented reactivation of the RAF-MEK-ERK pathway observed with each inhibitor alone and further enhanced inhibition of tumor growth in TNBC cell lines and xenografts. Inhibiting pan-RAS(on) RAS-GTP, with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation."
Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer
|
|
Austin A Whitman; Charles M Perou; Chinmaya U Joisa; Daniel Stover; David L Spector; Denis O Okumu; Gary L Johnson; H Shelton Earp; Ian C McCabe; James P Malone; Jen Jen Yeh; Jon S Zawistowski; Jose Felix Olivares-Quintero; Kevin R Mott; Lisa A Carey; Matthew D Sutcliffe; Michael P East; Patricia A Spears; Petra Erdmann-Gilmore; Philip M Spanheimer; Qiang Zhang; R Reid Townsend; Robert W Sprung; Shawn M Gomez; Sonam Bhatia; Xin Chen; Yi Xu; Yiling Mi
|